Erectile Dysfunction. The New Harbinger for Major Adverse Cardiac Events in the Diabetic Patient**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 51, Issue 21, 2008, Pages 2051-2052

  Kloner, Robert A ^a  

^a GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DISEASE ASSOCIATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; FAMILY HISTORY; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REPERFUSION INJURY; SILENT MYOCARDIAL INFARCTION; SMOKING; STROKE; TRANSIENT ISCHEMIC ATTACK; VASODILATATION;

CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; ERECTILE DYSFUNCTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; RISK FACTORS;

EID: 43749107044     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.11.084     Document Type: Editorial

References (13)

1. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk: The 2nd Princeton Consensus Conference. Am J Cardiology 96 (2005) 313-321
2. Thompson I.M., Tangen C.M., Goodman P.J., Probstfield J.L., Moinpour C.M., and Coltman C.A. Erectile dysfunction and subsequent cardiovascular disease. JAMA 294 (2005) 2996-3002
3. Blumentals W.A., Gomez-Caminero A., Joo S., and Vannappagari V. Should erectile dysfunction be considered as a marker for acute infarction?. Results from a retrospective cohort study. Int J Impot Res 16 (2004) 350-353
4. Kloner R.A., Mullin S.H., Shook T., et al. Erectile dysfunction in the cardiac patient: how common and should we treat?. J Urol 170 (2003) S46-S50
5. Montorsi F., Briganti A., Salonia A., et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 44 (2003) 360-364 discussion 364-5
6. Gazzaruso C., Solerte S.B., Pujia A., et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 51 (2008) 2040-2044
7. Ma R.C.-W., So W.-Y., Yang X., et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 51 (2008) 2045-2050
8. Montorsi P., Montorsi F., and Schulman C.C. Is erectile dysfunction the "Tip of the Iceberg" of a systemic vascular disorder?. Eur Urol 44 (2003) 352-354
9. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364 (2004) 689-696
10. ATP channels in rabbits. Am J Physiol Heart Circ Physiol 283 (2002) H1236-H1269
11. ATP channels in rabbits. J Mol Cell Cardiol 40 (2006) 405-411
12. Reffelmann T., and Kloner R.A. Effects of sildenafil on myocardial infarct size, microvascular function and acute ischemic left ventricular dilation. Cardiovasc Res 59 (2003) 441-449
13. Sesti C., Florio V., Johnson E., and Kloner R.A. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 19 (2007) 55-61